文献速递眼整形与眼眶眼底病与葡萄膜炎神经眼科

软组织填充剂致视力威胁性并发症:美国眼科学会报告

Vision-Threatening Complications of Soft Tissue Fillers: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2025-03-31

该报告系统回顾了注射用软组织填充剂眼部并发症的文献,纳入19篇III级证据研究,共198例视力丧失,透明质酸凝胶164例(83%)、自体脂肪29例(15%)。注射部位以鼻部90例(40%)最常见,中央及中上面部占189例(84%)。治疗干预虽安全但通常不能逆转视力丧失,视力不变137例(70%)、改善56例(28%)、恶化3例(2%)。

要点

  • 填充剂误入血管可致视力丧失,透明质酸凝胶最常见(164例,83%),鼻部为最常见注射部位(90例,40%)。
  • 中央及中上面部(鼻、额、眉间、额部)为高风险区域,共189例(84%)。
  • 透明质酸酶、溶栓剂等干预虽安全但通常不能逆转视力丧失,视力不变者137例(70%)。

核心结论

  • 软组织填充剂意外血管内注射与视力丧失相关,中央及中上面部为常见注射部位,提示这些区域视力丧失风险高于其他面部区域。
  • 透明质酸凝胶是最常见材料,但视力丧失也与其他多种填充材料相关。
  • 尚无循证方案用于管理视力丧失,但动脉内溶栓在再通闭塞动脉方面取得一定成功。

研究设计与样本

  • 美国眼科学会报告,通过PubMed数据库检索截至2024年5月的文献,限英文原创研究,描述软组织填充剂眼部并发症。
  • 共识别387篇文章,62篇全文审阅,19篇符合纳入标准,均被方法学家评为III级证据。

主要发现

  • 共198例因填充剂意外血管内注射导致的视力丧失,透明质酸凝胶164例(83%)、自体脂肪29例(15%)、胶原3例、聚左旋乳酸凝胶1例、羟基磷灰石钙1例。
  • 226个注射部位中,鼻部90例(40%)、额部56例(25%)、眉间26例(12%)、颞部21例(9%)、额部17例(7%)、鼻唇沟9例(4%)、面部2例、眶周2例、唇、眉、颊和上睑各1例。
  • 中央及中上面部(鼻、额、眉间、额部)为最常见部位,共189例(84%)。
  • 196例描述了闭塞事件后视力及最终视力:不变137例(70%)、改善56例(28%)、恶化3例(2%)。

关键数值与推荐

  • 常见治疗干预包括透明质酸酶注射(局部、眶内及动脉内)、动脉内注射溶栓剂和透明质酸酶、前房穿刺、静脉注射皮质类固醇、静脉注射甘露醇及高压氧。
  • 这些干预虽安全,但通常不能有效逆转视力丧失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有19篇文章均被方法学家评为III级证据。
  • 原文结论指出尚无循证方案用于管理视力丧失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review evidence on ocular complications of injectable soft tissue fillers, identify features associated with risk for vision loss, and assess the efficacy and safety of reported treatments. METHODS: Literature search of the PubMed database was last conducted in May 2024. Articles were limited to English-language original research describing ocular complications of soft tissue fillers. Of 387 articles identified, 62 were selected for full-text review. Nineteen articles met the criteria for inclusion. RESULTS: All 19 articles were assigned a level III rating by the panel methodologist. This assessment identified 198 cases of vision loss caused by accidental intravascular injection of filler material, hyaluronic acid gel in 164 cases (83%), autologous fat in 29 cases (15%), collagen in 3 cases, poly-L lactic acid gel in 1 case, and calcium hydroxyapatite in 1 case. The 226 injection sites, sometimes multiple locations, when described, were nose in 90 cases (40%); forehead in 56 cases (25%); glabella in 26 cases (12%); temple in 21 cases (9%) frontal in 17 cases (7%); nasolabial fold in 9 cases (4%); face in 2 cases; periocular in 2 cases; and lip, eyebrow, cheek, and upper eyelid in 1 case each. The central and upper midface (nose, forehead, glabella, frontal) were the most common sites (189 cases, 84%). The most common therapeutic interventions included hyaluronidase injection (local, orbital, and intra-arterial), intra-arterial injection of thrombolytic agents and hyaluronidase, anterior chamber paracentesis, IV corticosteroid, IV mannitol, and hyperbaric oxygen. These interventions, although safe, were usually not effective in reversing vision loss. Vision after the occlusive event and final vision were described in 196 cases; it was unchanged in 137 patients (70%), improved in 56 patients (28%), and worsened in 3 patients (2%). CONCLUSIONS: Inadvertent intravascular injection of soft tissue fillers is associated with cases of vision loss, with upper and central midface a common site of injection. This suggests zones of higher risk for vision loss compared with other facial areas. Hyaluronic acid gel was the most common material, although vison loss was also associated with a variety of other filler materials. No evidence-based protocol has been established for managing vision loss, but intra-arterial thrombolysis has had some success in recanalizing occluded arteries. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Foster J, Aakalu VK, Freitag SK, et al. Vision-Threatening Complications of Soft Tissue Fillers: A Report by the American Academy of Ophthalmology. Ophthalmology. 2025. PMID: 40167411. doi:10.1016/j.ophtha.2025.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。